Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
STAT News' Pharmalittle column on Tuesday June 30, 2026 disclosed that US lawmakers are investigating whether several large pharmaceutical companies have been involved in clinical trials at Chinese sites that helped advance China's military capability. The investigation runs parallel to the BIOSECURE Act (passed 2024) restricting US biotech contracting with named Chinese CDMOs and gene-sequencing companies, and to the structural anxiety about Chinese scientific output that biotech executives flagged at BIO 2026 last week. The Insilico Medicine (Hong Kong-headquartered) + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery pact announced June 22 at BIO 2026 opening sits inside this conversation, as do Chinese-API supply chains feeding US gray-market peptide vendors and the licensed-generic semaglutide flow from Indian and Chinese manufacturers post-March 2026 patent expiration. The lawmaker probe expands the regulatory aperture beyond the BIOSECURE Act's named-entity list toward broader scrutiny of US-China clinical-research cooperation. No specific drugmakers were publicly named in the Pharmalittle report.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026 at 11:59 PM ET. The proposal (Federal Register notice May 1, docket 2026-08552) cited 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. The final-comment filers split along expected lines. National Community Pharmacists Association (NCPA) and Alliance for Pharmacy Compounding (APC) argue for retention given continuing patient-access gaps for high-cost branded supply, particularly in rural and underserved markets where Hims & Hers and LifeMD telehealth penetration is lower. Partnership for Safe Medicines and the FDA's CDER drug safety arm support the exclusion, citing more than 455 adverse event reports linked to compounded semaglutide and 320+ reports tied to compounded tirzepatide as of early 2025, with a large fraction involving patient self-dosing errors from multidose vials. The FDA will publish its final determination in the Federal Register within several months of comment closure. Once finalized, large-scale compounded GLP-1 distribution through 503B outsourcing facilities ends; patient-specific 503A compounding may continue under narrow circumstances.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).
Pharmacy Times published an interview with Annie Lambert, PharmD, BCSCP, Wolters Kluwer's clinical program manager for compliance solutions, on Friday June 27, 2026, walking pharmacists through the operational response to the FDA's proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Three working points framed the guidance: the FDA's move signals a narrowing of large-scale compounding rather than an outright ban (503A pharmacies can still compound these agents under increased scrutiny); pharmacists should demonstrate fluency in the new regulatory rules and help patients weigh manufacturer-assistance programs (NovoCare $149-499/month, LillyDirect $299-449/month self-pay), direct-to-consumer channels, and the Medicare GLP-1 Bridge launching Wednesday July 1; patients should verify pharmacy licensure, question medication sourcing, and understand the distinction between FDA-approved branded products and compounded preparations. The guidance is the highest-profile professional-practice resource published in the comment-deadline week and is likely to circulate widely among the National Community Pharmacists Association and Alliance for Pharmacy Compounding memberships.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026, one day from this Sunday digest. The FDA proposed the exclusion on April 30 via a Federal Register notice published May 1 (docket 2026-08552), citing 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. Once the comment window closes and the FDA finalizes the determination, large-scale compounded GLP-1 distribution through 503B outsourcing facilities effectively ends. Patient-specific compounding through 503A pharmacies may continue under narrow circumstances (drug-shortage triggers, patient-specific clinical needs documented by the prescribing physician), but the bulk-compounding channel that supplied the 2022-2024 shortage-era compounded GLP-1 wave gets formally closed. The Partnership for Safe Medicines and FDA's CDER drug safety arm welcomed the proposal; compounding-pharmacy industry groups (APC, OFA) filed comments arguing for retention given continuing patient-access gaps for high-cost branded supply.
The week starting Monday June 29 stacks three federal regulatory milestones in three consecutive days. Monday: FDA's 503B GLP-1 exclusion public-comment window closes at 11:59 PM ET, finalizing the formal record on whether outsourcing facilities can continue compounding semaglutide, tirzepatide, and liraglutide. Tuesday June 30: registration for oral testimony at the July 23-24 Pharmacy Compounding Advisory Committee meeting closes (the meeting will vote 503A bulks list eligibility for BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; the written-comment docket FDA-2025-N-6895 remains open through July 22). Wednesday July 1: the Medicare GLP-1 Bridge demonstration goes live for eligible Part D beneficiaries at $50/month for Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen), with Humana serving as single central processor for prior authorization, claims adjudication, and pharmacy payment. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Medicare Part D. The three cutoffs collectively reshape the GLP-1 access architecture: branded direct supply expands through Medicare, bulk compounding through 503B narrows, and the non-GLP-1 503A peptide question goes to PCAC.
Dr. Catherine Varney, the University of Virginia Health Obesity Medicine Director, gave WSET (Roanoke-Lynchburg ABC affiliate) a syndicated local-TV interview published June 25, 2026 walking through the clinical realities of the unregulated peptide market. Her position on BPC-157 and TB-500 (both under FDA Pharmacy Compounding Advisory Committee review on July 23, 2026): animal-study evidence shows promise, while human clinical evidence remains thin, and she will not prescribe them. The interview frames the distinction patients often miss: FDA-approved weight-loss medications such as Ozempic and Wegovy are synthetic GLP-1 receptor agonists with rigorous Phase 3 evidence and post-marketing safety surveillance, while BPC-157, TB-500, and the broader unregulated stack are research-chemical products with no completed Phase 3 trial in any human indication. Varney's quoted position: 'I will not prescribe them.' She added that she will instead monitor patients who choose to take them, watch their labs for adverse effects, and emphasize lifestyle interventions with long-standing evidence (eating better and exercising more). The story sits inside a broader pattern of academic-medical-center clinicians publishing consumer-facing warnings ahead of PCAC.
Medscape published 'Unapproved Retatrutide Use Challenges Clinicians' on Friday June 26, 2026, documenting the scale of gray-market and clinic-channel retatrutide use that runs parallel to Eli Lilly's Phase 3 TRIUMPH program. Two anchor data points: retatrutide exposures reported to US poison-control centers averaged 95 cases per month in Q1 2026, a 265% increase from the average across the last four months of 2025; and at least 50 US clinics staffed by licensed physicians and nurse practitioners openly advertise the unapproved drug to weight-loss patients. The piece frames the practical challenge for primary-care and obesity-medicine clinicians whose patients arrive already taking retatrutide sourced from research-chemical vendors, online clinics, or compounding pharmacies operating outside the FDA bulks-list framework. The Drug Topics companion story (same week) added that the prescribing rate is 'alarming' to obesity-medicine specialty groups. The data lands the same week as Senator Hassan's June 25 letter to HHS Secretary RFK Jr. demanding answers on the FDA-Lilly compassionate-use grant to a 79-year-old patient: one VIP-adjacent individual received the real drug through a sanctioned pathway while at least 50 clinics distribute the unregulated version at scale.
In addition to the political escalation (Senator Hassan's June 25 letter to RFK Jr.; Rep. Ted Lieu's June 24 terminal-illness press conference; White House counterattacks against STAT reporter Lizzy Lawrence and Lieu), STAT News reported that 18 bioethics experts, obesity-medicine clinicians, and current and former US government health officials told the outlet that Eli Lilly's decision to grant compassionate-use access to retatrutide for a single 79-year-old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension 'struck them as unusual.' The core question raised by the bioethics community: why Lilly would offer compassionate use for a single patient when obesity is a population-scale condition affecting more than 100 million Americans, when expanded-access programs are typically structured around treatment INDs or intermediate-size protocols for broader access, and when the standard pathway for obesity-drug access is trial enrollment (TRIUMPH-2 obesity+T2D and TRIUMPH-3 obesity+CVD remain open). Jamy Ard (chief science officer, Advocate Health) said compassionate use is typically reserved for terminal illness. The bioethics critique is separate from the Trump-recipient speculation and is likely the more durable framing of the case as it moves through congressional oversight.
The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.
Senator Maggie Hassan (D-NH), ranking Democrat on the relevant committee, sent a formal written letter to HHS Secretary Robert F. Kennedy Jr. on June 25, 2026, demanding answers about whether President Trump (who turned 80 on June 14) is the 79-year-old patient who received compassionate-use access to Eli Lilly's investigational retatrutide. Hassan wrote: 'Reporting suggests that you have used this pathway to provide a highly anticipated medication for obesity to a single VIP individual for free, without providing that opportunity to other Americans.' Hassan also questioned Kennedy at a Senate committee hearing earlier the same day about 'vanity projects' at HHS. The June 25 letter is the first formal congressional action on the compassionate-use case originally reported by STAT News on June 23. Eli Lilly issued its first public statement to STAT News on June 25: 'We make these decisions following all applicable regulations.' The company has not disclosed how it evaluates retatrutide expanded-access requests or whether other applications are pending. Outside experts continue to question whether refractory obesity plus obstructive sleep apnea plus pulmonary hypertension meets the FDA's 'serious or immediately life-threatening' threshold typically reserved for terminal illness. The Senate letter creates an oversight track parallel to the political controversy already running through cable news and X.
California Rep. Ted Lieu (D) held a press conference on June 24, 2026 suggesting that President Trump canceled the signing of the bipartisan 21st Century ROAD to Housing bill earlier that day because he is fighting a terminal illness and dealing with side effects from an experimental drug. Lieu pointed to the STAT News retatrutide compassionate-use report and reasoned that compassionate-use access typically requires terminal illness. Lieu cited Trump being 'unable to stay awake at meetings, having visible arm weakness, and swelling in his hands' as supporting observations. White House Communications Director Steven Cheung responded by calling Lieu a 'dumba--' for the suggestion. The exchange escalated the political dimension of the retatrutide story from White House versus reporter (Kush Desai vs Lizzy Lawrence on June 23-24) to House Democrat versus White House Communications Director. The 21st Century ROAD to Housing Act is a bipartisan housing reform bill that Trump was scheduled to sign on Wednesday June 24, 2026, with the signing canceled the same day. The White House has not provided a public explanation for the cancellation beyond denying any connection to the retatrutide story.
Following STAT News reporter Lizzy Lawrence's June 23 scoop that the FDA and Eli Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, the White House response intensified June 23-24. Senior deputy press secretary Kush Desai posted on X that 'this application was not for the President' but did not explicitly deny that Trump (who turned 80 on June 14) had separately applied. After Lawrence reported the non-denial, Desai publicly called her 'an unserious gossip columnist.' The White House rapid response team added: 'No, it wasn't President Trump — and you people are truly sick and deranged.' The escalation moves the story from a closed regulatory-access question to an active political controversy, with outlets including The Hill, IBTimes UK, Slate, MS NOW, Hello Magazine, Tech Times, and The New Republic running parallel coverage. Outside medical experts continue to question whether refractory obesity plus OSA plus pulmonary hypertension meets the FDA's compassionate-use threshold typically reserved for immediately life-threatening illness.
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
STAT News broke June 23, 2026 that the FDA and Eli Lilly approved a single 79-year-old patient for compassionate-use access to retatrutide (Lilly's GIP/GLP-1/glucagon triple agonist still in Phase 3 development). Dr. Ranganath Muniyappa, a senior clinician at the National Institutes of Health, submitted the application in April citing diagnoses of refractory obesity, obstructive sleep apnea, and pulmonary hypertension. Outside medical experts told STAT the diagnoses don't clearly meet the compassionate-use threshold typically reserved for immediately life-threatening illness; Jamy Ard (chief science officer, Advocate Health) said 'compassionate use is usually reserved for terminal illness.' Compassionate use programs typically serve patients facing imminent death without alternatives, not refractory obesity even with severe comorbidities. The White House had to publicly deny that President Trump submitted the application. The patient's identity has not been confirmed. The episode crystallizes the peptide-access-equity tension at a moment when the broader US population continues to source retatrutide through gray-market research-chemical channels with no oversight.
The Centers for Medicare and Medicaid Services' GLP-1 Bridge demonstration launches Wednesday July 1, 2026 — 8 days from this digest's publication — providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy injection, Wegovy pill, and Zepbound KwikPen for chronic weight management. The program runs through December 31, 2027 as a short-term bridge to the broader BALANCE Model (launching January 2027 in Medicare Part D). Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, serves as the single central processor for prior authorization, claims adjudication, and pharmacy payment. CMS published the prior authorization fax form and prescriber/pharmacy educational materials on June 3, 2026. Eligibility requires BMI ≥30 (or ≥27 with comorbidities) and Part D enrollment. The launch arrives the same week as the Hims & Hers stock breakout and the FDA retatrutide compassionate-use disclosure — a coincidence that sharpens the peptide-access-equity debate as the broader US population continues to navigate $1,000+/month branded GLP-1 list prices.
Japan's Ministry of Health, Labour and Welfare granted Novo Nordisk a partial change approval of the manufacturing and marketing authorization for Wegovy (semaglutide) subcutaneous injection on June 19, 2026, adding an indication for metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis in patients with moderate to advanced fibrosis (stage F2 or F3). Wegovy is now the first approved MASH treatment in Japan. The approval is based on Part 1 of the global Phase 3 ESSENCE study where semaglutide 2.4 mg demonstrated statistically significant superiority to placebo on the co-primary endpoints of liver fibrosis improvement without worsening of MASH, and MASH resolution without worsening of fibrosis. Wegovy is co-promoted in Japan by Novo Nordisk Pharma and Sumitomo Pharma under the October 2025 co-promotion agreement. This is the second major MASH regulatory milestone for semaglutide after the FDA's August 2025 approval.
Australia's Therapeutic Goods Administration (TGA) escalated its peptide-products oversight to a formal compliance priority in a June 2026 media release, citing rising importation, expanding online advertising and supply, and hospitalisation data identifying serious adverse effects associated with unapproved peptides. Targeted products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295. The TGA emphasized that unapproved peptide products are not in the Australian Register of Therapeutic Goods and have not been evaluated for safety, quality, or efficacy. An eight-month operation involving TGA, the Australian Border Force, and Victoria Police seized about $2M worth of peptides, performance-enhancing drugs, and illicit steroids. Future compliance responses may include infringement notices, product seizures, import interventions, and civil or criminal penalties; advertising or promoting unapproved peptides through social media or influencer channels is likely to breach Australian therapeutic goods advertising laws. The escalation parallels the FDA's PCAC reclassification track and tightens the global regulatory squeeze on the gray-market peptide channel.